Pharmacokinetics of the orally administered decongestants pseudoephedrine and phenylpropanolamine in children. 1996

F E Simons, and X Gu, and W T Watson, and K J Simons
Facult of Medicine, Univesity of Manitoba, Winnipeg, Canada.

BACKGROUND There is little published, objective information about pseudoephedrine and phenylpropanolamine in the treatment of children. Our goal was to determine the pharmacokinetics of these medications in young subjects. METHODS In two sequential double-blind, parallel-group, single-dose studies, 21 children received either pseudoephedrine, 30 or 60 mg, or placebo, and 20 children received either phenylpropanolamine, 20 or 37.5 mg, or placebo. Before dosing and at intervals up to 7 hours after dosing, serum pseudoephedrine or phenylpropanolamine concentrations were measured, and pulse and blood pressure were recorded. In two children receiving each drug, these tests were also performed at 12 and 24 hours, and urine was collected from 0 to 12 and from 12 to 24 hours. RESULTS In children, the mean (+/-SEM) terminal elimination half-life values for pseudoephedrine, 3.1 +/- 0.5 hours, and for phenylpropanolamine, 2.6 +/- 0.6 hours, were significantly shorter than those found by other investigators in adults. Pharmacokinetics were not dose dependent in the dose ranges studied. CONCLUSIONS Further studies of pseudoephedrine and phenylpropanolamine should be performed in children with the use of objective measurements. The widespread use of these medications in young subjects should be reevaluated.

UI MeSH Term Description Entries
D008297 Male Males
D010665 Phenylpropanolamine A sympathomimetic that acts mainly by causing release of NOREPINEPHRINE but also has direct agonist activity at some adrenergic receptors. It is most commonly used as a nasal vasoconstrictor and an appetite depressant. Norephedrine,Dexatrim,Phenylpropanolamine Hydrochloride,Prolamine,Propagest,Triaminic DM,Hydrochloride, Phenylpropanolamine
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D004809 Ephedrine A phenethylamine found in EPHEDRA SINICA. PSEUDOEPHEDRINE is an isomer. It is an alpha- and beta-adrenergic agonist that may also enhance release of norepinephrine. It has been used for asthma, heart failure, rhinitis, and urinary incontinence, and for its central nervous system stimulatory effects in the treatment of narcolepsy and depression. It has become less extensively used with the advent of more selective agonists. Ephedrine Hydrochloride,Ephedrine Renaudin,Ephedrine Sulfate,Erythro Isomer of Ephedrine,Sal-Phedrine,Ephedrine Erythro Isomer,Hydrochloride, Ephedrine,Renaudin, Ephedrine,Sal Phedrine,SalPhedrine,Sulfate, Ephedrine
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor
D014663 Nasal Decongestants Drugs designed to treat inflammation of the nasal passages, generally the result of an infection (more often than not the common cold) or an allergy related condition, e.g., hay fever. The inflammation involves swelling of the mucous membrane that lines the nasal passages and results in inordinate mucus production. The primary class of nasal decongestants are vasoconstrictor agents. (From PharmAssist, The Family Guide to Health and Medicine, 1993) Decongestant,Decongestants,Nasal Decongestant,Vasoconstrictor Agents, Nasal,Vasoconstrictors, Nasal,Agents, Nasal Vasoconstrictor,Decongestant, Nasal,Decongestants, Nasal,Nasal Vasoconstrictor Agents,Nasal Vasoconstrictors

Related Publications

F E Simons, and X Gu, and W T Watson, and K J Simons
January 1982, Pediatria polska,
F E Simons, and X Gu, and W T Watson, and K J Simons
January 1995, Infection,
F E Simons, and X Gu, and W T Watson, and K J Simons
December 1996, Annals of the New York Academy of Sciences,
F E Simons, and X Gu, and W T Watson, and K J Simons
July 1989, American journal of obstetrics and gynecology,
F E Simons, and X Gu, and W T Watson, and K J Simons
September 1979, American journal of hospital pharmacy,
F E Simons, and X Gu, and W T Watson, and K J Simons
January 2000, Annals of the New York Academy of Sciences,
F E Simons, and X Gu, and W T Watson, and K J Simons
February 1974, Clinical pharmacology and therapeutics,
F E Simons, and X Gu, and W T Watson, and K J Simons
September 1990, Calcified tissue international,
F E Simons, and X Gu, and W T Watson, and K J Simons
January 1986, Journal of pharmaceutical sciences,
F E Simons, and X Gu, and W T Watson, and K J Simons
October 1974, Journal of pharmacokinetics and biopharmaceutics,
Copied contents to your clipboard!